免疫抑制剂对异常性膜性腎病的临床结果的影响
Ji-Young Choi1, Ho Jun Chin2, Hajeong Lee3
1Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Kidney research and clinical practice
|October 6, 2023
概括
免疫抑制剂显著改善了异常性膜性病的缓解率,特别是在年轻的女性患者中,女性患者具有高蛋白尿或良好的功能. 脏存活率相似,但免疫抑制剂组的感染风险在总队列中较高.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 异形膜性病 (IMN) 是成年人性综合征的主要原因.
- 关于IMN管理中的免疫抑制剂疗效存在有限的比较研究.
- 了解治疗效应对于优化患者的治疗结果至关重要.
研究的目的:
- 为了比较免疫抑制剂的疗效和安全性与IMN患者的保守治疗.
- 为了确定从免疫抑制疗法中受益最多的患者子组.
主要方法:
- 对489名IMN患者的回顾性分析.
- 倾向性得分匹配 (PSM) 创建可比较的组 (每组n=82) 用于保守和免疫抑制治疗.
- 主要结局:12个月后蛋白尿完全或部分缓解 (CR/PR).
- 二级结局:存率和感染发生率.
主要成果:
- 与保守治疗相比,免疫抑制剂治疗在12个月后导致CR/PR率显著上升,无论是总和PSM群体.
- 亚组分析显示,免疫抑制剂在65岁以下的患者,女性患者,蛋白尿 ≥4.0 g/g,或eGFR ≥60 mL/min/1.73 m2.
- 脏存活率在各组之间是可比的. 在总队列中,免疫抑制剂组的感染发病率较高,但在PSM群体中没有.
结论:
- 免疫抑制剂显著改善IMN患者的蛋白尿缓解.
- 较年轻的女性患者,患有重蛋白尿或保留功能,显示出最多的益处.
- 虽然免疫抑制可以增强缓解,但需要仔细监测感染,尽管PSM可以减轻风险.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
178
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
178
01:26Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
01:24Nephrotic Syndrome I : Introduction
9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9
01:24Chronic Kidney Disease II: Clinical Manifestations
13
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
13
01:24Nephrotic Syndrome III : Nursing Management
19
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
19
01:29Inflammatory Bowel Disease IV: Pharmacological Management
137
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
137